Medicenna Therapeutics Corp.

News & Events

Press Releases

In The Media

1. Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

   GlobeNewswire MAY 20, 2025 7:00 AM EDT
   MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media ...
   READ ARTICLE

2. Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting

   GlobeNewswire APR 30, 2025 9:00 AM EDT
   MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 S...
   READ ARTICLE

3. Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting

   GlobeNewswire APR 28, 2025 9:00 AM EDT
   Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alon...
   READ ARTICLE

4. Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

   GlobeNewswire APR 22, 2025 7:00 AM EDT
   TORONTO and HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&...
   READ ARTICLE

5. Medicenna to Present at Jones Healthcare and Technology Innovation Conference

   GlobeNewswire APR 1, 2025 7:00 AM EDT
   TORONTO and HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&...
   READ ARTICLE

6. Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

   GlobeNewswire MAR 26, 2025 7:00 AM EDT
   Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting Pre...
   READ ARTICLE

7. Medicenna Reports MDNA11's Compelling Anti-Cancer Activity is Associated with Significant Expansion of 'Stem-Like' Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

   GlobeNewswire FEB 25, 2025 7:00 AM EST
   MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that l...
   READ ARTICLE

8. Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

   GlobeNewswire FEB 13, 2025 10:28 AM EST
   - Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck&#...
   READ ARTICLE

9. Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

   GlobeNewswire FEB 5, 2025 7:00 AM EST
   TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&#...
   READ ARTICLE

10. Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

    GlobeNewswire DEC 13, 2024 8:30 AM EST
    Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-m...
    READ ARTICLE